Mitazalimab  (Synonyms: 米佐利单抗; ADC-1013; JNJ-64457107)

Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment^[1][2].

Human IgG1 lambda1

Human IgG1 lambda1, Isotype Control

Humanized

Mitazalimab（1 ng/mL-10 μg/mL）可激活人类前列腺肿瘤或卵巢肿瘤样本中的肿瘤相关巨噬细胞 (TAM)^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Mitazalimab（100 μg/小鼠；腹腔注射；单次剂量）激活 naïve hCD40tg 小鼠的脾脏树突细胞和 B 细胞，并在 OVA 再处理条件（200 μg；i.v.；3 次，连续 7 天）下，导致 OVA 特异性 CD8+ T 细胞扩增^[1]。
Mitazalimab（100 和 300 μg/小鼠；腹腔注射；接种后第 7、10 和 13 天）诱导携带 MB49（小鼠膀胱肿瘤细胞系）的肿瘤小鼠的血液中促炎细胞因子和趋化因子的释放，并改变肿瘤骨髓细胞组成，减少单核细胞和巨噬细胞，增加粒细胞^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2055640-86-1

液体

Colorless to light yellow

米佐利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda2

• [1]. Deronic A, et al. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. Cancer Immunol Immunother. 2021 Dec;70(12):3629-3642.  [Content Brief]

  [2]. Smith K E, et al. Mitazalimab, a potent CD40 agonist in combination with chemotherapy redirects and activates tumor infiltrating myeloid cells[J]. Cancer Research, 2022, 82(12_Supplement): 4155-4155.